Physician
Hematology
Dr. Daniel T. Milton, MD
|
|
Give Review
Daniel Milton is an expert in the field of Hematology. He attended Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a top medical college. Columbia University College of Physicians & Surgeons is ranked 8 in research and 52 in primary care medicine He has 1 awards "Regional Top Doctor". Dr. Daniel T. Milton has written publications. He has 17 publications published with PubMed. The lastest paper is: 'ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.' He accepts all Medicare patients.
Publications
- ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell ...
- Phase II study of pemetrexed and carboplatin plus bevacizumab With maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung can...
- Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung Cancer.
- Targeting Lewis Y (Le(y)) in small cell lung Cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
- Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients With acquired resistance to erlotinib or gefitinib followed by the add...
- Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung Cancer.
- Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for Rectal carcinoma: a phase II study with long-term follow-up.
- Molecular on/off switch.
- A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung Cancer.
- High incidence of disease recurrence in the Brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
- Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung Cancer.
- [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung Cancer].
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung Cancer.
- Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung Cancer: a phase II trial.
- Prompt control of bronchorrhea in patients with bronchioloalveolar Carcinoma treated with gefitinib (Iressa).
Schools
Columbia University College of Physicians And Surgeons
Northwestern University Med School
Meml Sloan Kettering Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Memorial Sloan-Kettering Cancer Center -
McGaw Medical Center of Northwestern University -
Columbia University College of Physicians & Surgeons
Drug Facts
| NPI NUMBER | 1205896818 | |
| NPPES Provider LastName | MILTON | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 46260 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1267.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 133.0 | |
| Percent Opioid Claims | 10.5 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205896818 |
| Last Name Of The Provider | MILTON |
| First Name Of The Provider | DANIEL |
| View All |